Novel treatment options for BCG naïve nonmuscle-invasive #BladderCancer: immune priming and immune checkpoint inhibitors. #LibraryResource Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss the current state of the evidence for ongoing trials > bit.ly/48gtwsA

#DragiWebdo n°414 : Dyslipidémies (recos Canada), colchicine (ANSM), asthme (recos ERS), maladie rénale chronique (reco HAS), infections respiratoires (HCSP), poussées d'arthrose, oméga-3 medicalement-geek.com/2023/10/dragi-…

Phenomenal vision & talk by Elizabeth Plimack MD on bladder preservation only with systemic Tx: we are not there yet, but heading rapidly! Need biomarkers (imaging & molecular)! @MattGalsky Andrea Necchi Robert Huddart💙 ESMO - Eur. Oncology OncoAlert #ESMO23 Shilpa Gupta Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Yüksel Ürün

Excellent summary of currently available intravenous and intravesical treatment options for BCG-unresponsive NMIBC by Dr. Joost Boormans UroToday.com #ESMO23

#ESMO23 Constance Thibault presenting the Phase1/2 NEMIO trial ddMVAC-Durva vs. ddMVAC-Durva/Treme ➡️48% CRR ➡️safety profile ✅ Let's wait for longer FU

TAR-210 (Sustained-release erdafitinib intravesical delivery system) in NMIBC pts w/ FGFR alterations 🔷Cohort 1: BCG-experienced/unresponsive HR NMIBC (papillary only HG Ta/T1; n=16) 🔷Cohort 3: IR NMIBC (LG Ta; chemoablation; n=27) 📌Efficacy: 82% recurrence-free in Cohort 1,

SunRISe-1: Updated results of TAR-200 monotherapy (intravesical sustained gemcitabine release delivery system) in HR BCG-unresponsive CIS +/- papillary (n=54) 🔷TAR-200: Dosed q3 weeks for first 24 wks, then q12 weeks through week 96 📌CR: 77%; 91% of responses ongoing (median

La Compo des #Springboks pour la finale de la Coupe du monde: #NZLvRSA #RWCFinal #RWC2023

Treatment for muscle invasive bladder cancer will change if the ongoing R3s are +ve. Neoadjuvant IO/ADC combination, bladder sparing approaches, intravesical therapy (TAR200) & ctDNA will improve outcomes and spare patients unnecessary treatments. This is the next chapter IMO.

Articles in Press: The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort buff.ly/48g97TT Kevin Shee, MD, PhD SamWashUro Hao Nguyen Matt Cooperberg Carroll, Peter #UroSoMe #Medtwitter

NOW OF: 5-year survival endpoints from the VESPER phase 3 RCT of perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer. thelancet.com/journals/lanon…

On September 19, 1991, while hiking in the Ötztal Valley in the Austrian Alps, German hikers Erika and Helmut Simon stumbled upon what they initially thought was the body of a recently deceased mountain climber. However, it turned out that this was a remarkably preserved mummy,

📽️ Nouvel épisode du « Canard historique » : 11 février 1961, création de l’OAS, un mouvement d’extrême droite opposé à l’indépendance de l’Algérie. ✏️ Dessins de J. Lap et Moisan

Patients with very high-risk #NMIBC receiving adequate #BCG therapy show better outcomes than predicted by EAU risk classification in this retrospective multi center cohort 👉lnkd.in/dffDCqc8 European Urology UroToday.com Juan Gómez Rivas Benjamin Pradere Laura S. Mertens EAU Young Academics

EV and pembrolizumab doubling PFS and OS in 1st line UC compared to chemotherapy NEJM

New ESMO - Eur. Oncology guidlines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available annalsofoncology.org/article/S0923-…

Long term results Oligopelvis study European Urology Congrats Supiot Stéphane GETUG 🔆Median FU = 6.1 yr 🔆N=67 🔆Rates of grade 2+ toxicities among patients without progression at 5 yr was 4% for GU toxicities, and 4% for GI, respectively. sciencedirect.com/science/articl…

🔘 Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed? #UrothelialCarcinoma #bladdercancer buff.ly/4azxVb0